PE20240895A1 - Anticuerpos del receptor antitransferrina y usos de los mismos - Google Patents
Anticuerpos del receptor antitransferrina y usos de los mismosInfo
- Publication number
- PE20240895A1 PE20240895A1 PE2024000361A PE2024000361A PE20240895A1 PE 20240895 A1 PE20240895 A1 PE 20240895A1 PE 2024000361 A PE2024000361 A PE 2024000361A PE 2024000361 A PE2024000361 A PE 2024000361A PE 20240895 A1 PE20240895 A1 PE 20240895A1
- Authority
- PE
- Peru
- Prior art keywords
- amino acid
- seq
- acid sequence
- cdr2
- cdr3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163239630P | 2021-09-01 | 2021-09-01 | |
| US202263388088P | 2022-07-11 | 2022-07-11 | |
| PCT/US2022/042196 WO2023034409A1 (en) | 2021-09-01 | 2022-08-31 | Anti-transferrin receptor antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240895A1 true PE20240895A1 (es) | 2024-04-24 |
Family
ID=83508506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024000361A PE20240895A1 (es) | 2021-09-01 | 2022-08-31 | Anticuerpos del receptor antitransferrina y usos de los mismos |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11827702B2 (enExample) |
| EP (1) | EP4396231A1 (enExample) |
| JP (1) | JP2024534880A (enExample) |
| KR (1) | KR20240107202A (enExample) |
| AU (1) | AU2022340568A1 (enExample) |
| CA (1) | CA3230796A1 (enExample) |
| CL (1) | CL2024000642A1 (enExample) |
| CO (1) | CO2024003577A2 (enExample) |
| CR (1) | CR20240139A (enExample) |
| IL (1) | IL311175A (enExample) |
| JO (1) | JOP20240042A1 (enExample) |
| MX (1) | MX2024002753A (enExample) |
| PE (1) | PE20240895A1 (enExample) |
| TW (1) | TW202328187A (enExample) |
| WO (1) | WO2023034409A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024187057A2 (en) | 2023-03-08 | 2024-09-12 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
| CN116735864B (zh) * | 2023-08-15 | 2023-11-10 | 迦进生物医药(上海)有限公司 | 评估TfR1抗体血液安全性的试剂盒 |
| IL327952A (en) * | 2023-10-26 | 2026-06-01 | Biogen Ma Inc | Anti-transferrin receptor antibodies and uses thereof |
| CN121517563A (zh) * | 2024-08-09 | 2026-02-13 | 东北制药集团股份有限公司 | 人源化的靶向TfR1的抗体及其应用 |
| WO2026076250A1 (en) * | 2024-10-03 | 2026-04-09 | Genentech, Inc. | Lipid nanoparticles for delivery to the cns from systemic administration |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
| ATE154245T1 (de) | 1990-03-27 | 1997-06-15 | Salk Inst For Biological Studi | Verfahren zur zellwachstumshinderung und dazu nützliche verbindungen |
| US5648469A (en) | 1992-04-20 | 1997-07-15 | The Salk Institute For Biological Studies | Monoclonal antibodies reactive with transferrin receptor cytoplasmic domain |
| JP4756032B2 (ja) | 2004-03-31 | 2011-08-24 | アトナーゲン アクチエンゲゼルシャフト | 胎児赤血球細胞に対して特異性を有するモノクローナル抗体 |
| WO2005094364A2 (en) | 2004-03-31 | 2005-10-13 | Chimeric Technologies, Inc. | Iga antibody protein as a cytotoxic drug |
| EP1740616B1 (en) | 2004-04-30 | 2011-12-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-tfr antibody. |
| KR101295139B1 (ko) | 2004-06-07 | 2013-08-12 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | 트랜스페린 리셉터 항체 |
| AU2005287406B2 (en) | 2004-07-26 | 2011-08-18 | Biogen Ma Inc. | Anti-CD154 antibodies |
| WO2006096653A2 (en) | 2005-03-04 | 2006-09-14 | Biogen Idec Ma Inc. | Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues |
| US7736647B2 (en) | 2005-06-15 | 2010-06-15 | Monoclonal Antibodies Therapeutics | Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| FR2953841B1 (fr) | 2009-12-16 | 2011-12-30 | Centre Nat Rech Scient | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
| FR2959416B1 (fr) | 2010-05-03 | 2012-06-22 | Monoclonal Antibodies Therapeutics Mat Biopharma | Utilisation d'anticorps anti-cd71 pour la preparation d'un medicament |
| CN103443125B (zh) | 2010-11-30 | 2019-05-03 | 霍夫曼-拉罗奇有限公司 | 低亲和力血脑屏障受体抗体及其用途 |
| US9598496B2 (en) | 2011-05-09 | 2017-03-21 | Perseus Proteomics Inc. | Antibody capable of specifically recognizing transferrin receptor |
| TWI450727B (zh) | 2011-12-29 | 2014-09-01 | 財團法人工業技術研究院 | 抗人類輸鐵蛋白受體的單域抗體與其應用 |
| TW201333040A (zh) | 2012-01-06 | 2013-08-16 | Bioalliance Cv | 抗－輸鐵蛋白受器之抗體及其使用方法 |
| MX367126B (es) | 2012-08-29 | 2019-08-06 | Hoffmann La Roche | Transporte para atravesar la barrera hematoencefálica. |
| DK2918603T3 (en) | 2012-11-08 | 2018-10-15 | Univ Miyazaki | ANTIBODY STANDING TO SPECIFICALLY RECOGNIZE TRANSFERRIN RECEPTOR |
| WO2014144060A1 (en) | 2013-03-15 | 2014-09-18 | Alper Biotech, Llc | Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof |
| SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
| US9499628B2 (en) | 2013-06-14 | 2016-11-22 | Children's Hospital Medical Center | Method of boosting the immune response in neonates |
| JP6616189B2 (ja) * | 2013-12-25 | 2019-12-04 | Ｊｃｒファーマ株式会社 | 血液脳関門を通過する新規抗トランスフェリン受容体抗体 |
| PL3092251T3 (pl) | 2014-01-06 | 2021-08-02 | F. Hoffmann-La Roche Ag | Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg |
| CA2967830A1 (en) * | 2014-11-14 | 2016-05-19 | Ossianix, Inc. | Tfr selective binding compounds and related methods |
| JP6779876B2 (ja) * | 2014-11-19 | 2020-11-04 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 抗ｃｄ７１抗體類、可活化之抗ｃｄ７１抗體類及使用彼等之方法 |
| AU2016282334B2 (en) | 2015-06-24 | 2022-07-21 | F. Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies with tailored affinity |
| CA2990785C (en) | 2015-06-24 | 2024-11-12 | Jcr Pharmaceuticals Co., Ltd. | ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER |
| IL257065B (en) | 2015-07-22 | 2022-07-01 | Inatherys | Antibodies to tfr for use in the treatment of proliferative and inflammatory diseases |
| MX2018003822A (es) | 2015-10-02 | 2018-06-22 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso. |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| DK3473270T5 (da) | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| US20190375819A1 (en) | 2016-10-29 | 2019-12-12 | Rhode Island Hospital | Glycosylated transferrin receptor 1 tumor antigen |
| TWI833178B (zh) | 2016-12-26 | 2024-02-21 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之新穎抗人類運鐵蛋白受體抗體 |
| CA3053381A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Engineered polypeptides |
| WO2019032955A1 (en) | 2017-08-10 | 2019-02-14 | Denali Therapeutics Inc. | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
| CN118638787A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| CN111683972A (zh) | 2018-02-05 | 2020-09-18 | Jcr制药股份有限公司 | 用于将药剂递送至肌肉的方法 |
| CA3108328A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva |
| CN112930193A (zh) | 2018-08-02 | 2021-06-08 | 达因疗法公司 | 肌肉靶向复合物及其在治疗肌肉萎缩中的用途 |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| EP3830127A4 (en) | 2018-08-02 | 2022-06-29 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating pompe disease |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| EP3829594A4 (en) | 2018-08-02 | 2022-05-11 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY |
| US20210322562A1 (en) | 2018-08-02 | 2021-10-21 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating centronuclear myopathy |
| AU2019315593B2 (en) | 2018-08-02 | 2026-05-21 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
| CA3108386A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating friedreich's ataxia |
| CN112955154A (zh) | 2018-08-02 | 2021-06-11 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途 |
| WO2020104479A1 (en) | 2018-11-20 | 2020-05-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies |
| US20240148891A1 (en) | 2019-10-18 | 2024-05-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CN115427448A (zh) | 2020-01-10 | 2022-12-02 | 达因疗法公司 | 肌肉靶向复合物及其用途 |
| EP4087653A4 (en) | 2020-01-10 | 2024-06-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2021154477A1 (en) * | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US20230256112A1 (en) | 2020-07-23 | 2023-08-17 | Dyne Therapeutics, lnc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| AU2021414227A1 (en) | 2020-12-31 | 2023-07-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
-
2022
- 2022-08-31 CA CA3230796A patent/CA3230796A1/en active Pending
- 2022-08-31 AU AU2022340568A patent/AU2022340568A1/en active Pending
- 2022-08-31 US US17/900,161 patent/US11827702B2/en active Active
- 2022-08-31 KR KR1020247010811A patent/KR20240107202A/ko active Pending
- 2022-08-31 PE PE2024000361A patent/PE20240895A1/es unknown
- 2022-08-31 JP JP2024513785A patent/JP2024534880A/ja active Pending
- 2022-08-31 WO PCT/US2022/042196 patent/WO2023034409A1/en not_active Ceased
- 2022-08-31 CR CR20240139A patent/CR20240139A/es unknown
- 2022-08-31 EP EP22783097.3A patent/EP4396231A1/en active Pending
- 2022-08-31 TW TW111132949A patent/TW202328187A/zh unknown
- 2022-08-31 MX MX2024002753A patent/MX2024002753A/es unknown
- 2022-08-31 IL IL311175A patent/IL311175A/en unknown
-
2023
- 2023-10-19 US US18/490,319 patent/US20240158494A1/en active Pending
-
2024
- 2024-02-29 JO JOJO/P/2024/0042A patent/JOP20240042A1/ar unknown
- 2024-03-01 CL CL2024000642A patent/CL2024000642A1/es unknown
- 2024-03-21 CO CONC2024/0003577A patent/CO2024003577A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202328187A (zh) | 2023-07-16 |
| JP2024534880A (ja) | 2024-09-26 |
| CO2024003577A2 (es) | 2024-06-27 |
| US20240158494A1 (en) | 2024-05-16 |
| MX2024002753A (es) | 2024-05-20 |
| WO2023034409A1 (en) | 2023-03-09 |
| EP4396231A1 (en) | 2024-07-10 |
| US20230131379A1 (en) | 2023-04-27 |
| JOP20240042A1 (ar) | 2024-02-29 |
| CL2024000642A1 (es) | 2024-09-13 |
| CR20240139A (es) | 2024-06-14 |
| KR20240107202A (ko) | 2024-07-08 |
| US11827702B2 (en) | 2023-11-28 |
| AU2022340568A1 (en) | 2024-03-28 |
| CA3230796A1 (en) | 2023-03-09 |
| IL311175A (en) | 2024-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20091269A1 (es) | Moleculas de union al receptor ox40 humano | |
| PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| AR123083A1 (es) | Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos | |
| PE20221256A1 (es) | Anticuerpos dirigidos a flt3 y uso de los mismos | |
| RU2009124591A (ru) | Соединения | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| PE20081478A1 (es) | Anticuerpos cd44 | |
| PE20210377A1 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| AR085091A1 (es) | Anticuerpos anti-kit y sus usos | |
| CN101512008A (zh) | 白介素-13结合蛋白 | |
| CO6251370A2 (es) | Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma | |
| AR079458A2 (es) | Anticuerpo monoclonal quimerico que se une a cd45 | |
| US20240101675A1 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| EA201490020A1 (ru) | Растворимые белки для применения в качестве терапевтических средств | |
| JP2023538117A (ja) | 神経免疫疾患のためのｃｄ３／ｃｄ２５抗体 | |
| PE20240883A1 (es) | Anticuerpos capaces de unirse a cd27, variantes y usos de los mismos | |
| AR121898A1 (es) | Compuestos y métodos dirigidos a interleucina-34 | |
| AR129995A1 (es) | Moléculas de unión al antígeno anti-steap1 y sus usos | |
| AR125142A1 (es) | Moléculas de unión terapéuticas |